LivaNova Reports Strong Q4 & FY25 Results, Raises 2026 Guidance, and Secures Major VNS Therapy Reimbursement Boost

summarizeSummary

LivaNova reported strong Q4 and full-year 2025 results, provided optimistic 2026 guidance, and announced a significant increase in CMS reimbursement for its VNS Therapy for Drug-Resistant Epilepsy, alongside FDA approval for a new digital health platform.

check_boxKey Events

• Strong Q4 and Full-Year 2025 Financial Performance

  LivaNova reported fourth-quarter revenue of $360.9 million, up 12.1% reported and 9.5% constant-currency/organic. Full-year 2025 revenue reached $1.39 billion, an increase of 10.7% reported and 9.7% constant-currency. Adjusted diluted EPS for Q4 was $0.86 and for the full year was $3.90, reflecting strong operational execution.

• Positive 2026 Guidance Issued

  The company expects full-year 2026 constant-currency revenue growth between 6.0% and 7.0%. Adjusted diluted earnings per share for 2026 is projected to be in the range of $4.15 to $4.25, indicating continued growth.

• Significant VNS Therapy Reimbursement Increase

  Effective January 1, 2026, LivaNova received increased provider reimbursement from U.S. CMS for VNS Therapy for Drug-Resistant Epilepsy procedures, with hospital outpatient payments rising approximately 48% for new patient implants and 47% for end-of-service procedures, significantly reducing a known barrier to procedure penetration.

• FDA Approval for Cloud-Based Digital Health Platform

  The company received U.S. FDA approval for its cloud-based digital health platform, establishing a foundation to deliver greater convenience and deeper insights throughout the DRE patient journey.

auto_awesomeAnalysis

LivaNova PLC delivered robust financial performance in Q4 and full-year 2025, marked by double-digit revenue growth and expanding operating margins. The company also issued positive guidance for 2026, projecting continued revenue growth and increased adjusted diluted earnings per share. A significant catalyst is the increased U.S. CMS reimbursement for VNS Therapy for Drug-Resistant Epilepsy procedures, which is expected to substantially reduce a key barrier to market penetration. Additionally, FDA approval for a new cloud-based digital health platform strengthens the foundation for future DRE patient management. While the company recorded a substantial one-time SNIA environmental liability expense impacting GAAP results, the focus on adjusted operational metrics and future growth drivers suggests a positive outlook.